This page has been robot translated, sorry for typos if any. Original content here.

Attention! Information is for reference only!
Before taking, be sure to consult a doctor!
SITE ONLY DIRECTORY. NOT A PHARMACY! We do not sell medicines! None!

Medication Description: Molgramostim

Molgramostim *.

Synonyms: Leucomax, Leucomax [name of the drug company "Sandoz" (Switzerland)].

Molgramostim has a certain immunotropic activity; it stimulates the growth of T-lymphocytes (but not B-lymphocytes). The main specific feature of molgramostyma is its ability to stimulate leukopoiesis, therefore, it is used as an anti-leukopenic agent.

Until recently, there was not enough effective specific anti-leukopenic drugs. To a certain extent, leucopoiesis is stimulated by drugs leucogen, methylthiouracil, pentoxyl, and batilol (see). For stimulation of leukopoiesis, immunostimulating preparations thymalin, sodium nucleinate, etc. are also used.

The recent creation of molgramostyma has been an important contribution to the therapy of leukopenia. This drug is a recombinant (genetically engineered) human granulocyte-macrophage colony-stimulating factor. Thus, molgramostim is an endogenous factor involved in the regulation of hematopoiesis and the functional activity of leukocytes. It stimulates the proliferation and differentiation of hematopoietic cell precursors, as well as the growth of granulocytes, monocytes; increases the content of mature cells in the blood.

The drug leykomaks (molgrammostim) is a highly purified water-soluble protein consisting of 127 amino acid residues. Leukomax is used for the treatment and prevention of leukopenia in pathological conditions involving a violation of myeloid hematopoiesis. The drug accelerates the recovery of myeloid hematopoiesis; contributes to the prevention of potential infectious complications of leukopenia.

Doses and regimen of drug administration depend on the indications and the course of the pathological process.

When aplastic (hypoplastic) anemia is injected under the skin at 3 µg / kg (0.003 µm / kg) once a day. The therapeutic effect usually occurs in 2 to 4 days, after which the dose is selected individually so as to maintain the number of leukocytes at the desired level, usually not higher than 10 * 10 9 / l.

In case of leukopenia, which occurred during chemotherapy of tumors, 5-10 μg / kg is administered under the skin once a day. The drug begins to be administered 1 day after the completion of the cycle of chemotherapy. Simultaneously with chemotherapy, leukomax is not used. Leukomax is administered in the indicated doses for 7–10 days.

The cycle of chemotherapy is repeated 48 hours after stopping the administration of leucomax.

Leucomax is also used in the treatment of AIDS patients. When monotherapy is administered under the skin 1 mg / kg once a day; when combined with specific antiviral drugs (see Ganciclovir) - 1 - 3 - 5 mcg / kg per day. The effect, as a rule, is observed on the 2nd - 4th day. Then the dose is selected individually (every 3–5 days) in order to maintain the leukocyte count at the desired level, usually not higher than 10 * 10 9 / l.

For bone marrow transplantation, 5-10 μg / kg of leucomax per day is injected.